MRVI vs PVLA: stock comparison and AI forecast
Maravai Lifesciences Holdings, Inc. (MRVI) and Palvella Therapeutics, Inc. (PVLA) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
MRVI Maravai Lifesciences Holdings, Inc.
- Price
- $7.52 +90.9% · 6M
- Market Cap
- $1.95B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
PVLA Palvella Therapeutics, Inc.
- Price
- $175.92 +55.3% · 6M
- Market Cap
- $2.53B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- PVLA is 1.3 times larger than MRVI by market capitalization ($2.53B against $1.95B).
- Over the last six months MRVI returned +90.9% and PVLA +55.3%.
- MRVI carries 1.33 times debt per unit of equity, against 0.21 times for PVLA.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | MRVI | PVLA |
|---|---|---|
| Market Cap | $1.95B | $2.53B |
| P/B Ratio | 9.97x | 12.78x |
| EPS | $-0.81 | $-6.26 |
| Book Value/Share | $0.75 | $13.76 |
| Revenue/Share | $0.82 | – |
| FCF/Share | $-0.05 | – |
Profitability & Margins
| Metric | MRVI | PVLA |
|---|---|---|
| ROE | – | -37.9% |
| ROA | – | -31.3% |
| ROIC | -17.1% | -31.3% |
| Gross Margin | 39.1% | – |
| Operating Margin | -45.4% | – |
| EBT Margin | -54.2% | – |
| Tax Rate | 0.3% | 0.0% |
Financial Health
| Metric | MRVI | PVLA |
|---|---|---|
| Current Ratio | 4.66x | 16.01x |
| Quick Ratio | 3.35x | – |
| D/E Ratio | 1.33x | 0.21x |
| Financial Leverage | 3.06x | 1.21x |
| Interest Coverage | -5.2x | -8.9x |
| Working Capital | $121M | $224M |
Cash Flow
| Metric | MRVI | PVLA |
|---|---|---|
| Operating Cash Flow | -$5M | -$43M |
| Free Cash Flow | -$13M | – |
| Capital Spending | -$7M | – |
| FCF/Sales | -5.9% | – |
| CapEx/Sales | 3.5% | – |
Operational Efficiency
| Metric | MRVI | PVLA |
|---|---|---|
| Asset Turnover | 0.35x | – |
| Receivables Turnover | 8.3x | – |
| Inventory Turnover | 3.0x | – |
| Fixed Assets Turnover | 1.6x | – |
| Days Sales Outstanding | 44 days | – |
| Days Inventory | 122 days | – |
| Payables Period | 18 days | – |
| Cash Conversion Cycle | 148 days | – |
Income Statement
| Metric | MRVI | PVLA |
|---|---|---|
| Total Revenue | $213M | – |
| Operating Income | -$97M | -$70M |
| Net Income | – | -$75M |
| R&D Expense | $15M | $40M |
| SG&A Expense | $123M | – |
| Cost of Goods Sold | $130M | – |
Dividend & Shareholder Information
| Metric | MRVI | PVLA |
|---|---|---|
| Shares Outstanding | 260M | 14M |
MRVI vs PVLA: stock comparison and AI forecast
Which is bigger, MRVI or PVLA?
PVLA is 1.3 times larger than MRVI by market capitalization ($2.53B against $1.95B).
Which stock performed better over the last six months, MRVI or PVLA?
Over the last six months MRVI returned +90.9% and PVLA +55.3%.
Which one does Intratio's AI model rank higher, MRVI or PVLA?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.